Landrich Quarterly Newsletter – Q3 2026: Advancing Longevity & Precision Healthcare
By David Petrich, Landrich Group Co-Founder and VP of Quality and Regulatory
Four hundred years ago, the philosopher Sir Francis Bacon advocated the extension of the healthy human lifespan as an achievable scientific goal. In his books The Advancement of Learning and History of Life and Death, Bacon argued that immortality, or “continuance”, was a natural human aspiration. In his view, the ultimate purpose was not merely the selfish pursuit of more time and pleasure for its own sake. Instead, it was to provide humanity with more time to learn, create, and contribute to society.
The Landrich Group is deeply committed to technological innovation for healthy aging, particularly solutions for the “deadly quintet” of chronic illnesses – cardiovascular, cancer, respiratory, dementia, and diabetes – responsible for most death and disease in industrialized countries.
Precision Medicine. Cancer therapy has been transformed by companion diagnostics (CDx) and targeted drugs. The Landrich Group is currently supporting a landmark multicenter clinical trial advancing companion diagnostics and targeted therapies for cancers in myeloid cells, which play a key role in blood production. The trial, conducted by the National Cancer Institute (NCI), focuses on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), two aggressive forms of cancer. Subjects enrolled in the trial undergo rapid genetic testing and personalized therapies for these cancers affecting blood and bone marrow cells.
Gene Therapy. Technologies that target cellular and genetic systems, such as cellular rejuvenation, gene activation, and sequence editing, aim to reduce physical and mental decline. Landrich actively supports clients working in the gene therapy space, with services such as GCP mock audits and BIMO inspection readiness activities. Landrich also actively monitors international developments in these fields, such as Yamanaka Factors research in Japan.
Wearables. Devices that enable preventative wellness and healthy habit formation have received widespread adoption. In the United States, the chronic diseases with the largest public impact are conditions we already know how to substantially reduce through better exercise, diet, sleep, stress management, and avoidance of risky substances. Smartwatches, fitness trackers, and sensor technology have enabled a new generation of devices that are increasingly receiving regulatory support to help solve our population health crises. Wearables align with the FDA’s Healthcare at Home initiative to advocate for preventative health measures and increase access to underserved populations.
Point-of-Care. The COVID-19 pandemic demonstrated the need for robust infrastructure in an age of globalization and the potential for rapidly evolving infectious diseases. These technologies are essential to realizing the promise of healthy longevity in developing economic zones, such as sub-Saharan Africa, which will comprise the majority of the world’s population in the second half of the 21st century. Landrich actively supports international device makers at the forefront of point-of-care technology, such as miDiagnostics and rapid screening devices for early detection of meningitis and encephalitis.
The modern world faces challenges that are, in some ways, linked to our unprecedented health and prosperity. During the past one hundred years, life expectancy has more than doubled. Around the world, governments are amassing record debt, much of it connected to the elderly. In the United States, 40 percent of the federal spending is dedicated to Medicare and Social Security. In Japan and Western European countries, pensions are the single biggest line item in the budget. In the future, healthy aging will be a strategic imperative for the viability of nation-states and every other type of social institution.
The Landrich Group is passionate about staying abreast of emerging technologies and the ever-changing regulatory landscape to bring safe and effective healthcare products to market in partnership with our clients. We are confident that our clients and colleagues are well-positioned to address these challenges. Francis Bacon defied the conventional wisdom of the 17th century, which assumed that life would always get worse the longer it lasted. In his novel The New Atlantis, he imagined an ideal society where people shared a common sense of purpose based on the advancement of knowledge of human health and happiness. We believe that every day, through our work with all of you, we are getting one step closer to that world.
